Evidence map›Paper›PMID 38229401›Full record

ArticleApplied microbiology and biotechnology2024

Impact of Bacillus licheniformis from yaks following antibiotic therapy in mouse model.

Zhibo Zeng, Saisai Gong, Chuxian Quan, Shimeng Zhou, Muhammad Fakhar-E-Alam Kulyar, Mudassar Iqbal, Yan Li, Xiang Li, Jiakui Li

Open access · goldAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Zhibo ZengCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Saisai GongCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Chuxian QuanCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Shimeng ZhouCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Muhammad Fakhar-E-Alam KulyarCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Mudassar IqbalCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Yan LiCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
Xiang LiCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China. xxianglli@mail.hzau.edu.cn.
Jiakui LiCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China. lijk210@mail.hzau.edu.cn.ORCID http://orcid.org/0000-0002-6065-6648
Huazhong Agricultural University · CNIslamia University of Bahawalpur · PKTibet University · CN

Funding

Chinese Agricultural Research Systems CARS-37Development of a Yak Pasteurella Vaccine (YPV) Chimeric Fusion Protein Gene Vaccine Fund XZ202001ZY0044NKey Project of Tibet Autonomous Region XZ202001ZY0044NKey Project of Tibet Autonomous Region XZ202101ZD0002N-05
6 · The paper itself

Abstract

Gut microorganism (GM) is an integral component of the host microbiome and health system. Abuse of antibiotics disrupts the equilibrium of the microbiome, affecting environmental pathogens and host-associated bacteria alike. However, relatively little research on Bacillus licheniformis alleviates the adverse effects of antibiotics. To test the effect of B. licheniformis as a probiotic supplement against the effects of antibiotics, cefalexin was applied, and the recovery from cefalexin-induced jejunal community disorder and intestinal barrier damage was investigated by pathology, real-time PCR (RT-PCR), and high-throughput sequencing (HTS). The result showed that A group (antibiotic treatment) significantly reduced body weight and decreased the length of jejunal intestinal villi and the villi to crypt (V/C) value, which also caused structural damage to the jejunal mucosa. Meanwhile, antibiotic treatment suppressed the mRNA expression of tight junction proteins ZO-1, claudin, occludin, and Ki67 and elevated MUC2 expression more than the other Groups (P < 0.05 and P < 0.01). However, T group (B. licheniformis supplements after antibiotic treatment) restored the expression of the above genes, and there was no statistically significant difference compared to the control group (P > 0.05). Moreover, the antibiotic treatment increased the relative abundance of 4 bacterial phyla affiliated with 16 bacterial genera in the jejunum community, including the dominant Firmicutes, Proteobacteria, and Cyanobacteria in the jejunum. B. licheniformis supplements after antibiotic treatment reduced the relative abundance of Bacteroidetes and Proteobacteria and increased the relative abundance of Firmicutes, Epsilonbacteraeota, Lactobacillus, and Candidatus Stoquefichus. This study uses mimic real-world exposure scenarios by considering the concentration and duration of exposure relevant to environmental antibiotic contamination levels. We described the post-antibiotic treatment with B. licheniformis could restore intestinal microbiome disorders and repair the intestinal barrier. KEY POINTS: • B. licheniformis post-antibiotics restore gut balance, repair barrier, and aid health • Antibiotics harm the gut barrier, alter structure, and raise disease risk • Long-term antibiotics affect the gut and increase disease susceptibility.

Indexed as

Bacillus licheniformisIntestinal DiseasesProbioticsAnimalsAnti-Bacterial AgentsBacillotaCattleCephalexinDietary SupplementsMiceAnti-Bacterial AgentsCephalexinAntibioticBacillus licheniformisGut microbiotaProbiotic supplementationYaks

Identifiers

PMID38229401
PMCPMC13498003
OpenAlexW4390914178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.